Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: Results of the LESS trial

HIV Clinical Trials

Volumn 11, Issue 5, 2010, Pages 239-247

  Cohen, Calvin ^a   DeJesus, Edwin ^b   LaMarca, Anthony ^c   Young, Benjamin ^d   Yau, Linda ^e   Patel, Lisa ^e   Vavro, Cindy ^e   Wire, Mary Beth ^e   Wannamaker, Paul ^e   Shaefer, Mark ^e  

^a Boston Community Research Initiative of New England   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Therafirst Medical Center   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

antiretroviral therapy; fosamprenavir; HIV; ritonavir; simplification

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DECREASED APPETITE; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IMMUNOLOGICAL MONITORING; MAJOR CLINICAL STUDY; MALE; NAIL PICKING; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AGED; CARBAMATES; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TRIGLYCERIDES; YOUNG ADULT;

EID: 79251638846     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1105-239     Document Type: Article

References (14)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009:1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 21, 2010.
3. ® [prescribing information]. Abbott Park, IL: Abbott Laboratories; 2010.
4. Shafran S, Mashinter L, Roberts S. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentratrions. HIV Med. 2005;6:421-425.
5. US Food and Drug Administration. FDA approves LEXIVA (fosamprenavir calcium). Press release; October 21, 2003.
6. Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetics and safety of amprenavir and ritonavir following multipledose, co-administration to healthy volunteers. AIDS. 2001;15:1009-1018.
7. Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1, 400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrobial Agents Chemother. 2007;51:560-565.
8. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrobial Agents Chemother. 2002;46:746-754.
9. Wood R, Eron J, Arasteh K, et al. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis 2004;39:591-594.
10. ® [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
11. Hirsch MS, Gunthard H F, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47:266-285.
12. Hicks C, DeJesus E, Sloan L, et al. Comparison of oncedaily fosamprenavir boosted with either 100 or 200 mg ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Human Retroviruses. 2009;25:395-403.
13. Kurowski M, Walli RK, Breske A, et al. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS. 2007;21:1368-1370.
14. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5.